Panbela Therapeutics Financials

Based on the key indicators related to Panbela Therapeutics' liquidity, profitability, solvency, and operating efficiency, Panbela Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.
  
Please note, the presentation of Panbela Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Panbela Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Panbela Therapeutics' management manipulating its earnings.

Panbela Therapeutics Stock Summary

Panbela Therapeutics competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Revelation Biosciences, Palisade Bio, and Virax Biolabs. Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Panbela Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS69833W1071
CUSIP69833Q100 69833W107 69833W206 69833W305 86664M206 86664M107 69833W404
LocationMinnesota; U.S.A
Business Address712 Vista Boulevard,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.panbela.com
Phone952 479 1196
CurrencyUSD - US Dollar

Panbela Therapeutics Key Financial Ratios

Panbela Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Panbela Therapeutics's current stock value. Our valuation model uses many indicators to compare Panbela Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Panbela Therapeutics competition to find correlations between indicators driving Panbela Therapeutics's intrinsic value. More Info.
Panbela Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Panbela Therapeutics' earnings, one of the primary drivers of an investment's value.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Consideration for investing in Panbela Stock

If you are still planning to invest in Panbela Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Panbela Therapeutics' history and understand the potential risks before investing.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance